XIENCE™ Family of Drug-Eluting Stents

The World's Leading Drug-Eluting Stents (DES), with Unparalleled Clinical Outcomes¹

XIENCE™ Family of Drug-Eluting Stents

Market-Leading Everolimus

The market-leading choice for XIENCE™ Stent is everolimus, which is a proven therapeutic drug.²

An ideal drug for DES has these characteristics:

  • Safe over the long term
  • Stable over time
  • Compatible with polymer
  • Cytostatic and anti-inflammatory
  • Effective at varying doses for a wide therapeutic window

The everolimus drug provides all these features.

Everolimus Elution Rate Matches Restenosis Cascade for Optimal Endothelisation Rate3

The release of everolimus aligns with the vessel's restenosis cascade. This, in turn, maximises the drug's efficacy against restenosis and minimises the drug's effect of re-endothelialisation, which facilitates vessel restoration and function.

 

Everolimus Elution Correlates to Restenosis Cascade

The Xience Stent drug elution profile shows that 100% of the drug is eluted at 120 days.

XIENCE™ Stent Uses Low Dose of Everolimus3,4

Everolimus is a well established anti-proliferative drug. The concentration of everolimus used with XIENCE™ Stent is low, at 100 µg/cm². These histological images below show healthy, fully healed vessels at a concentration that is 8x the dose used on the XIENCE™ stent. Images were gathered using a pre-clinical animal model.


Everolimus Safety at 8x Drug Dose
 

Everolimus safety at 8x its regular dose on XIENCE™ DES

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
  2. XIENCE Skypoint™ Stent Instruction For Use (IFU). Refer to IFU for additional information. 
  3. Perkins L, et al. J Interven Cardiol. 2009;22:S28-S40; Bennett J, Biologics: Targets and Therapy. 2013;7:149-159; Meredith I et al. J Am Cardiol Intv. 2009;2:977-985.
  4. Data on file at Abbott.
Explore Abbott's technologies for your needs.

Explore Abbott's technologies for your needs.

Access personalised education and training

Access personalised education and training

How can we help? Reach Abbott’s fast support here.

How can we help? Reach Abbott’s fast support here.

MAT-2413712 V1.0